SCHEMBL23218587

SCHEMBL23218587

CCOC(=O)Cc1ccccc1OCc1coc2c(CN3CCN(C(=O)OC(C)(C)C)CC3)cc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 4/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
MMP1 P03956 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
ADAM17 P78536 1/20 0.39
NPSR1 Q6W5P4 2/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CD274 Q9NZQ7 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
KMT2A Q03164 3/20 0.36
MAPT P10636 2/20 0.36
MPI P34949 2/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852778 1.00 ALDH1A1 (0.40) ALDH1A1KDM4EPOLBL3MBTL1MMP1
SCHEMBL28736146 0.90 KDM4E (0.39) ALDH1A1KDM4EPOLBNPSR1TSHR
SCHEMBL23219084 0.88 KDM4E (0.39) ALDH1A1KDM4EPOLBHSD17B10KMT2A
SCHEMBL29852448 0.88 CCR5 (0.39) ALDH1A1KDM4EPOLBTSHRCD274
SCHEMBL23218351 0.88 CCR5 (0.39) ALDH1A1KDM4EPOLBTSHRCD274
SCHEMBL23218445 0.86 CCR5 (0.40) ALDH1A1KDM4EL3MBTL1NPSR1TSHR
SCHEMBL29852963 0.85 CFD (0.45) ALDH1A1KDM4EPOLBL3MBTL1NPSR1
SCHEMBL23218395 0.85 CFD (0.45) ALDH1A1KDM4EPOLBL3MBTL1NPSR1
SCHEMBL23218227 0.84 CCR5 (0.37) ALDH1A1KDM4EPOLBL3MBTL1NPSR1
SCHEMBL23229202 0.82 CCR5 (0.40) ALDH1A1KDM4ENPSR1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB ALDH1A1 2667/4885KDM4E 4172/4885POLB 3530/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALDH1A1 3142/4885KDM4E 4491/4885POLB 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.